Denali Therapeutics (DNLI) FCF Margin (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly FCF Margin of 6213.65% for Q3 2023, down 472044.0% year-over-year from N/an in Q3 2022, and down 15691.74% quarter-over-quarter from 39.35% in Q2 2023.
Denali Therapeutics (DNLI) FCF Margin (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported FCF Margin for 6 consecutive years, with 6213.65% the latest figure, recorded in Q3 2023.
- In Q3 2023, FCF Margin fell 472044.0% year-over-year to 6213.65%; the TTM figure through Jun 2024 stood at 31736.31% (down 3164776.0% YoY), while the FY2023 annual figure was 112.22%, up 12070.0% from the prior year.
- FCF Margin retreated to 6213.65% in Q3 2023 per DNLI's latest filing, from 39.35% in the prior quarter.
- Across five years, FCF Margin topped out at 162.2% in Q4 2020 and bottomed at 106482.69% in Q1 2020.
- Historically, FCF Margin has averaged 6701.87% across 5 years, with a median of 696.66% in 2021.
- Annual changes were most pronounced in 2020 — FCF Margin sank 10572426 bps — and 2021, when it soared 10581316 bps.
- Denali Therapeutics' FCF Margin stood at 881.54% in 2019, then jumped by 118 bps to 162.2% in 2020, then sank by 194 bps to 152.03% in 2021, then plunged by 376 bps to 723.79% in 2022, then plunged by 758 bps to 6213.65% in 2023.
- Business Quant data shows DNLI's FCF Margin at 6213.65% in Q3 2023, 39.35% in Q2 2023, and 184.62% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -2,713.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,713.85% |
| Sep 30, 2023 | -6,213.65% |
| Jun 30, 2023 | -39.35% |
| Mar 31, 2023 | -184.62% |
| Dec 31, 2022 | -723.79% |
| Sep 30, 2022 | -1,493.21% |
| Jun 30, 2022 | -94.74% |
| Mar 31, 2022 | -171.38% |
| Dec 31, 2021 | -152.03% |
| Sep 30, 2021 | -780.21% |
| Jun 30, 2021 | -344.33% |
| Mar 31, 2021 | -669.53% |
| Dec 31, 2020 | 162.20% |
| Sep 30, 2020 | 13.29% |
| Jun 30, 2020 | -751.54% |
| Mar 31, 2020 | -106,482.69% |
| Sep 30, 2019 | -881.54% |
| Jun 30, 2019 | -1,068.03% |
| Mar 31, 2019 | -758.43% |
| Dec 31, 2018 | 73.00% |